Dr. Sokoloff named chief of urology at University of Arizona
Mitchell H. Sokoloff, MD, has been appointed chief of the section of urology and professor of surgery at the University of Arizona department of surgery. In this capacity, his objective will be to expand clinical, educational, and research programs in laparoscopy, voiding dysfunction, and urologic cancers, and to build a pediatric urology program in collaboration with university and community physicians.
Mitchell H. Sokoloff, MD, has been appointed chief of the section of urology and professor of surgery at the University of Arizona department of surgery. In this capacity, his objective will be to expand clinical, educational, and research programs in laparoscopy, voiding dysfunction, and urologic cancers, and to build a pediatric urology program in collaboration with university and community physicians.
Dr. Sokoloff also has been instrumental in developing nerve-sparing and robotic operations for men with prostate cancer and in expanding the role of nephron-sparing surgery and laparoscopy in the management of kidney cancer. He also combines novel and innovative drug therapies with conventional surgery to improve the outcomes for patients with aggressive and high-risk, locally advanced, or metastatic tumors. He has received more than $1 million in peer-reviewed grant support from the U.S. Department of Defense for his research.
Dr. Sokoloff was formerly at Oregon Health and Sciences University, where he served as chief of urologic oncology and director of the OHSU Robotic Surgery Program.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
